Shoichiro Sato

机构：Eli Lilly (United States) · ORCID：0000-0001-8551-434X

发表论文 218 篇 · 总被引 5059 次 · h-index 37

代表论文

• Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data (2020 · The Lancet · 被引 190)
• Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings (2019 · Journal of Thrombosis and Thrombolysis · 被引 52)
• Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study (2021 · Stroke · 被引 37)
• Sex differences in treatment, radiological features and outcome after intracerebral haemorrhage: Pooled analysis of Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage trials 1 and 2 (2020 · European Stroke Journal · 被引 29)
• D-dimer level and outcome of minor ischemic stroke with large vessel occlusion (2020 · Journal of the Neurological Sciences · 被引 29)
• Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation (2024 · JAMA Neurology · 被引 27)